Multiple DNA Binding Activities of the Novel Site-specific Recombinase, Piv, from Moraxella lacunata*

Deborah M. Tobiason, Anne G. Lenich, and Anna C. GlasgowDagger

From the Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The recombinase, Piv, is essential for site-specific DNA inversion of the type IV pilin DNA segment in Moraxella lacunata and Moraxella bovis. Piv shows significant homology with the transposases of the IS110/IS492 family of insertion elements, but, surprisingly, Piv contains none of the conserved amino acid motifs of the lambda  Int or Hin/Res families of site-specific recombinases. Therefore, Piv may mediate site-specific recombination by a novel mechanism. To begin to determine how Piv may assemble a synaptic nucleoprotein structure for DNA cleavage and strand exchange, we have characterized the interaction of Piv with the DNA inversion region of M. lacunata. Gel shift and nuclease/chemical protection assays, competition and dissociation rate analyses, and cooperativity studies indicate that Piv binds two distinct recognition sequences. One recognition sequence, found at multiple sites within and outside of the invertible segment, is bound by Piv protomers with high affinity. The second recognition sequence is located at the recombination cross-over sites at the ends of the invertible element; Piv interacts with this sequence as an oligomer with apparent low affinity. A model is proposed for the role of the different Piv binding sites of the M. lacunata inversion region in the formation of an active synaptosome.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Numerous site-specific DNA recombination systems and DNA transposition systems have been characterized biochemically and have been found to follow two distinct chemical pathways for DNA cleavage and strand transfer in recombination (reviewed in Refs. 1-4). Site-specific recombination, mediated by the recombinases of the lambda -integrase and Hin/resolvase families, involves a two-step transesterification reaction in which the intermediate is a covalent recombinase-DNA linkage. This covalent attachment is the result of nucleophilic attack on the DNA phosphodiester backbone by a hydroxyl group of the conserved serine (Hin/resolvase), or tyrosine (lambda -integrase), of the recombinase. In the second transesterification reaction, the phosphodiester linkages of the exchanged DNA strands are restored (reviewed in Refs. 2 and 3). In contrast, DNA transposition, mediated by transposases containing the catalytic DDE amino acid motif, utilizes a hydrolysis reaction for cleavage at the ends of the transposable element. This first cleavage leaves 3'-OH ends to act directly as the attacking nucleophile in a one-step trans-esterification reaction resulting in strand exchange. Resolution of the transposition process involves DNA replication or DNA repair activity to fill in gaps left at the target site due to the staggered cut mediated by the transposase and the 3' hydroxyl groups at the element ends (reviewed in Refs. 1 and 4).

These features of the recombination reactions mediated by site-specific recombinases and transposases suggest that a group of related recombinases would not mediate both site-specific recombination and transposition. Therefore, it is surprising that the site-specific recombinase Piv, which directs site-specific DNA inversion in Moraxella lacunata and Moraxella bovis, exhibits significant homology to the transposases of the IS110/IS492 family of IS elements (approximately 25-35% amino acid identity and 45-55% similarity, 5). Furthermore, Piv and the IS110/IS492 transposases do not appear to be related to the site-specific recombinases of the lambda -Int or Hin/resolvase families or the transposases containing the DDE motif (4). Therefore, Piv and the IS110/IS492 transposases may define a new family of DNA recombinases.

The homology between Piv and the IS110/IS492 transposases includes several highly conserved amino acid regions (5), which, based on mutational analyses, contain functionally relevant amino acid motifs.1 Although there is no completely conserved DNA sequence among all the IS elements and the Piv invertible DNA segment, there is a consensus sequence for the ends of a subgroup of the IS elements, which is also found overlapping the recombination sites of the Piv invertible element.1 To determine if indeed Piv and the IS110/IS492 transposases define a new family of DNA recombinases that utilize a common mechanism for both site-specific recombination and transposition, we must characterize the recombination reactions mediated by Piv and transposases from the IS110/IS492 family. As a first step in understanding the mechanism for Piv-mediated assembly of a synaptic nucleoprotein complex, DNA cleavage, and strand exchange, we have characterized the interactions of Piv with the invertible DNA segment of Moraxella lacunata.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents-- DNase I was obtained from Worthington Biochemical Corp. Amylose resin, restriction enzymes, T4 DNA ligase, Klenow (exo-), and T4 polynucleotide kinase were purchased from New England Biolabs (NEB). Pfu DNA polymerase was obtained from Stratagene. The His tag XPRESS purification system and the TA cloning kit were purchased from Invitrogen. Radionucleotides were obtained from NEN Life Science Products. Isopropyl-1-beta -D-galactopyranoside (IPTG),2 dithiothreitol, and EDTA were purchased from Sigma. Dimethyl sulfate was purchased from Aldrich.

Plasmids-- The pAG607 plasmid is composed of the pMal-C2 vector (NEB) containing the piv gene inserted into the XmnI and BamHI sites such that it is in frame directly downstream of a factor Xa protease site in the malE gene. The piv gene was obtained by the polymerase chain reaction (PCR) from the pMxL1 plasmid, subclone of M. lacunata inversion region provided by C. Marrs (6), using Pfu DNA polymerase and the primers: 5'-GCCAGCACGTGTCTAAAACTTACATTG-3' and 5'-CCTAAGCTTCTAGGATACCAATAAAT-3'. Similarly, the piv gene from pMxL1 was PCR-amplified with the primers: 5'-CTCGTCTCGAGTTCATGAATGCGTTTGTCAAAAG-3' and 5'-CAGTTCACATATGTCTAAAACTTACATTGGGATT-3', cleaved with XhoI and NdeI, and inserted into the same restriction sites in pET21a (Novagen). This placed piv in frame with a COOH-terminal His6 tag sequence, creating the Piv-His6 expression vector, pAG1300.

A 245-bp fragment was generated from the pMxL1-dl24 plasmid (6) using Pfu DNA polymerase and the primers 5'-CATAGGATCCAAAATTACCTGCCAGACATC-3' and 5'-CCGGAATTCGCTAACCTTACACTCATAC-3'. This 245-bp fragment, containing the strong upstream binding site (sub1), was cloned into the pCR2.1 vector (TA cloning kit, Invitrogen). The resulting plasmids, pAG604 and pAG605, contain sub1 in opposite orientations. The inserted DNA was sequenced (T7 Sequenase version 2.0 DNA sequencing kit; Amersham Pharmacia Biotech) to check for any mutations due to the PCR reaction.

To construct the DNA inversion test plasmid pAG862, a 5865-bp DNA fragment containing the invertible segment was obtained by partial digestion of pMxL1 with EcoRI. This fragment was gel-purified and ligated into EcoRI-digested pACYC184 (NEB) creating the pAG850 plasmid. To inactivate piv, the Omega  fragment encoding the SpcR/SmR genes was recombined into the piv gene of pAG850 by homologous recombination with piv::Omega on the pMxL5 plasmid (6) in the Rec+ strain JM101 (NEB). The recombinant plasmid, pAG862, was confirmed by restriction digestion and DNA sequencing.

Protein Purification-- To produce the Piv protein fused at its amino terminus to maltose-binding protein (MBP-Piv), DH5alpha containing pAG607 was grown in Luria broth to OD600 = 0.5, induced with 0.5 mM IPTG, aerated at 37 °C for 2 h, and lysed in a French pressure cell. Crude extract was immediately loaded onto an amylose column, washed with column buffer (20 mM Tris-Cl, pH 7.4, 500 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol), and then eluted with 10 mM maltose in column buffer (7, 8). Fractions were collected and frozen in 20% or 30% glycerol at -20 °C. Protein concentration was quantitated using the Bio-Rad DC protein assay kit.

To produce the His6-tagged Piv, pAG1300 was introduced into BL21(DE3) (Novagen), grown to mid-log phase in Luria broth, then induced with 1 mM IPTG. After 1 h aeration at 37 °C, cells were collected by centrifugation, resuspended in 20 mM phosphate, 500 mM NaCl, pH 7.8, and lysed in a French pressure cell at 4 °C. The lysate was centrifuged at 30,000 × g. The supernatant was loaded onto an Invitrogen ProBond column (Ni2+ affinity column). Following washes with 500 mM NaCl, 20 mM phosphate, pH 7.8 buffer, protein was eluted with an imidazole step gradient (50, 200, 350, and 500 mM). Piv-His6 eluted at 300 mM imidazole. The protein was dialyzed into 20 mM phosphate, 500 mM NaCl, pH 7.8, and 30% glycerol at 4 °C and stored at -20 °C.

Antibody Production and Purification-- Antibody to the Piv protein was produced in rabbits injected with purified MBP-Piv protein (BAbCO; Berkeley Antibody Company). Nonspecific antibodies were removed from the rabbit sera by absorption to whole cells of DH5alpha cultures, followed by multiple passages over a Sepharose column bound with Escherichia coli proteins and MBP. This affinity column was made by lysing a culture of pMal-C2/DH5alpha that had been induced with 0.5 mM IPTG to express the MBP protein, then binding the proteins from this lysate to cyanogen bromide-activated Sepharose resin using the protocol of the resin manufacturer (Amersham Pharmacia Biotech). The eluate was stored at 4 °C.

Western Blot and SDS-PAGE Analysis-- SDS-polyacrylamide gel electrophoresis was performed using the protocol of Sambrook et al. (9). Western blot analysis was accomplished following the method of Ausubel et al. (10) with the following modifications; polyvinylidene difluoride membrane (Bio-Rad) was used for blotting, and the blot was probed with a 1:400 dilution of partially purified Piv antibody. The protein markers were SDS-PAGE standards, low range, or Kaleidoscope prestained standards (for Western blots) from Bio-Rad.

Inversion Assay-- DH5alpha containing pAG862, pAG862 and pAG607 or containing pAG862 and pMal-C2 were grown to OD600 = 0.6, induced with 0.05 mM IPTG, and incubated for 2 h at 37 °C. Plasmids were extracted using an alkaline lysis protocol (9) and digested with HindIII and KpnI. The restriction digests were examined on a 0.8% SeaKem (FMC Bioproducts) agarose gel. The DNA was visualized by ethidium bromide staining and documented by digital imaging of the UV-illuminated gel.

Labeling of DNA Fragments Used in DNA Binding Assays-- Double-stranded DNA oligonucleotides, INV and SUB (see "Results"), were labeled with [gamma -32P]ATP using T4 polynucleotide kinase following the protocols of Sambrook et al. (9). pAG604 and pAG605 were digested with SpeI and EcoRV to obtain 298-bp fragments containing the sub1 site to be used in DNase I protection assays. These fragments were labeled at the SpeI site with [alpha -32P]ATP using Klenow (exo-) DNA polymerase under conditions recommended by the manufacturer with the modification of incubating the reactions at 25 °C; the labeled fragments were electrophoresed on a 5% polyacrylamide gel, electroeluted from the gel, and stored at -20 °C. The pMxL1-dL24 plasmid, a deletion derivative of pMxL1, provided by C. Marrs (6), and the pMxL1 invR fragment (obtained by PCR from pMxL1, using Pfu DNA polymerase and the primers: 5'-GCCAGCACGTGTCTAAAACTTACATTG and 5'-CCATACACCATCAGCAGCACG) were digested with various restriction enzymes as indicated under "Results." The DNA fragments created were labeled with [alpha -32P]dATP or dCTP using Klenow (exo-) polymerase, gel-purified, and stored at -20 °C.

Gel Electrophoresis Retardation Assays-- Gel electrophoresis retardation, or gel shift, assays were initiated by mixing MBP-Piv protein with each radiolabeled DNA fragment (5 × 10-12 M) in 1× binding buffer: 80 mM KCl, 20 mM Tris-Cl, pH 7.6, 5 mM CaCl2, 250 mg/ml poly(C), 1 mM dithiothreitol, and 50 mg/ml bovine serum albumin (NEB). The reactions were incubated for 20 min at room temperature, immediately loaded onto a nondenaturing polyacrylamide gel, and run at 4 °C in 0.5× TBE buffer. For the competition assays, increasing amounts of competitor DNA ranging from 1 to 500 molar excess was added to the reaction before addition of the protein. The specific DNA competitors were the SUB and INV double-stranded oligonucleotides and the nonspecific DNA competitor was a 39-bp oligonucleotide: 5'-TTAAGATCGATGACGTCAGATCTGAGCTCGATACTCGAG annealed to 5'-CTCGAGTATCGAGCTCAGATCTGACGTCATCGATC.

Nuclease and Chemical Cleavage Assays-- For the DNase I protection assays performed at the sub1 site, the 298-bp fragments from pAG604 and pAG605, labeled on the top strand and bottom strand for sub1 (5 × 10-10 M), were incubated for 20 min at room temperature with or without MBP-Piv (7 × 10-6 M) in 1× binding buffer. DNase I protection assays were performed in binding buffer plus 5 mM MgCl2 with 0.02 units of DNase I as described previously (11). Chemical cleavage using the Maxam and Gilbert sequencing reactions A/G and C/T were performed with the same labeled fragments (12). The footprinting and sequencing reactions were run on a 6% sequencing polyacrylamide gel.

At the site of inversion, dimethyl sulfate interference assays were performed as described previously (11). Indirect DNase I and 1,10-phenanthroline-copper protection assays were also performed at the site of inversion following the protocol described by Kuwabara and Sigman (13) with the following modifications for the DNase I protection assay: gel slices were treated with DNase I in 1× binding buffer plus 5 mM MgCl2 for 5-8 min before quenching the reaction with the addition of 20 mM EDTA.

Cooperativity Studies-- Gel electrophoresis retardation assays were performed with labeled DNA fragments (5 × 10-12 M) and increasing amounts of MBP-Piv protein ranging from 0.6 to 1582 nM for binding to SUB and 0.6 to 4560 nM for binding to INV. Binding of MBP-Piv (P) to each DNA binding site (X) is represented by the equation: K = [P]n[X]/[PnX], which translates into: ln([PnX]/[X]) n ln[P] - ln[K]. [P] is the concentration of MBP-Piv monomers, [Pn] is the concentration of active MBP-Piv oligomers, n is the number of active monomers in the oligomer, [PnX] is the concentration of bound DNA, and [X] is the concentration of unbound DNA. A plot of ln[P] versus ln([PnX]/[X]) gives a line with slope n (14). The amount of bound and unbound DNA was quantitated using a PhosphorImager: 445SI with ImageQuant software (Molecular Dynamics).

Dissociation Rate Analysis-- Binding assays were performed in 1× binding buffer. Labeled, double-stranded oligonucleotide (5 × 10-12 M) was incubated with MBP-Piv protein (6 × 10-7 M) as indicated for 20 min at room temperature. Unlabeled, competitor oligonucleotide (2.5 × 10-8 M) was added at time zero. At the indicated times, 20-µl aliquots were loaded onto a 10% nondenaturing polyacrylamide gel running at 120 V. Following electrophoresis, the gels were dried and imaged with a PhosphorImager: 445SI. ImageQuant software was used to quantitate the label in the bands corresponding to MBP-Piv-DNA complexes and unbound DNA. The fraction of the total DNA in the reaction that was bound by MBP-Piv was calculated by dividing the amount of labeled DNA present in the shifted complexes by the total labeled DNA in the reaction (i.e. the combined complexed and unbound DNA fragments quantitated for each reaction). The percent bound DNA was plotted as a function of the time after addition of competitor DNA. The half-life for each complex was the time required for a 50% reduction in protein-DNA complex due to dissociation of the MBP-Piv DNA complex.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Purification of Piv Protein for in Vitro DNA Binding Assays-- Based on the sequence of the piv gene, the Piv protein is predicted to be a 322-amino acid polypeptide with a Mr of 36,935 and an isoelectric point of 10.72. To facilitate purification of Piv, M. lacunata piv was introduced into the expression vector pMal-C2, fusing malE to the 5' end of piv (pAG607) to produce the fusion protein, MBP-Piv. MBP-Piv (79 kDa) was soluble and expressed at high levels. Affinity chromatography (amylose resin) was used to purify the MBP-Piv fusion protein for use in DNA binding assays. Fig. 1A shows a Coomassie-stained SDS-PAGE gel containing samples from a crude lysate used for purification of MBP-Piv and fractions collected from the 10 mM maltose elution of protein bound to the amylose column. ImageQuant analysis of a digital image of a Coomassie-stained, SDS-polyacrylamide gel containing serial dilutions of the purified protein indicated that the fractions used in all the following experiments are approximately 85% full-length MBP-Piv protein (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Expression of MBP-Piv. A, SDS-polyacrylamide gel, stained with Coomassie Blue, showing 20 µl of crude lysate from DH5alpha containing pAG607 after induction for 2 h with 0.5 mM IPTG and 20 µl from 3 ml fractions (fraction numbers 3-10) collected during elution with 10 mM maltose (in column buffer) of the bound proteins on an amylose column loaded with 50 ml of the crude lysate. B, Western blot analysis of the proteins expressed from cultures, uninduced (U) or induced (I) with 0.5 mM IPTG, containing pMal-C2 (MBP) or pAG607 (MBP-Piv), and loaded onto a 10% SDS-polyacrylamide gel along with affinity purified MBP-Piv (4 µg of purified protein). The bands corresponding to MBP-Piv and the location where MBP is seen on the corresponding SDS-PAGE gel are indicated with arrows. "Marker" designates the protein molecular weight standards (Bio-Rad), and the molecular sizes are indicated (kDa). In both the Coomassie-stained gel (A) and the Western blot (B), there appears to be some degradation of MBP-Piv; the purity of the protein preparations were based only on full-length fusion protein.

Fig. 1B shows Western blot analysis of expression of the MBP-Piv fusion protein from pAG607 using polyclonal antisera raised against MBP-Piv and affinity-purified to obtain anti-Piv antisera as described under "Experimental Procedures." MBP-Piv could be detected in the soluble fraction of a crude lysate prepared from DH5alpha cells containing pAG607 after induction with 0.5 mM IPTG (Fig. 1B, lanes 3 and 4). The affinity-purified antibodies are specific for Piv as no cross-reactivity with MBP alone was observed (Fig. 1B, lane 2).

Cleavage of MBP-Piv with the protease factor Xa, which recognizes a specific cleavage site between MBP and Piv in the fusion protein, resulted in cleavage at the fusion junction sequence and, unfortunately, also within Piv itself. Because this additional cleavage site prevented separation of the full-length Piv protein from MBP by Factor Xa treatment, we determined whether the MBP-Piv fusion protein could carry out the functions of wild type Piv.

An in vivo inversion assay was used to qualitatively estimate recombinase activity as an indication of functional protein-DNA interactions (Fig. 2). DH5alpha was cotransformed with a DNA inversion test plasmid, pAG862, and expression plasmids encoding either MBP alone (pMal-C2), or MBP-Piv (pAG607). After overnight expression of MBP or MBP-Piv, recombination of the invertible segment on pAG862 was assayed by restriction enzyme digestion of isolated plasmid DNA. In the original orientation of the test plasmid, digestion with HindIII and KpnI results in two bands, of 5.7 and 1.0 kb. If there is MBP-Piv-mediated inversion, the same digestion will yield two different unique bands, of 4.1 and 2.6 kb. With MBP alone, no inversion products are seen, whereas, in the presence of MBP-Piv, approximately 50% of the test plasmid is in the inverted orientation (Fig. 2). In a similar inversion assay, wild type Piv also directed inversion to yield approximately 50% of either orientation, representing an equilibrium point in the inversion reaction (data not shown). Thus, these results indicated that the MBP-Piv fusion is a functional recombinase; consequently, the uncleaved MBP-Piv fusion protein was used in subsequent in vitro DNA binding studies.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 2.   In vivo inversion activity of the MBP-Piv fusion protein. An inversion assay was performed as described under "Materials and Methods" using the inversion substrate plasmid, pAG862, which is phase-locked in the tfpI expressing orientation. The pMal-C2 and pAG607 plasmids, which express MBP and MBP-Piv, respectively, were used to test the ability of MBP-Piv to invert the Moraxella DNA segment (in parentheses) in E. coli. Restriction digestion with HindIII (H) and KpnI (K) yields distinct DNA fragments indicating that inversion has occurred, as represented in the diagram beside the EtBr-stained agarose gel of these inversion products. These DNA fragments are designated I and Q, denoting the orientation of the pilin genes, tfpQ and tfpI, relative to their promoter in the inversion substrate. The I bands are marked with *, and the Q bands are indicated with arrows. The plasmids are not drawn to scale.

Piv Binding Sites within the Inversion Region of M. lacunata-- Based on the binding specificity of other site-specific recombinases and transposases (reviewed in Refs. 1 and 2), we expected that Piv would bind DNA sequences encoding the cross-over sites for inversion (invL and invR) as well as possible accessory sites involved in recombination or regulation of piv expression. An assay for Piv DNA binding sites within the inversion region was carried out using gel electrophoresis mobility shift assays (EMSA; data not shown) with a series of restriction fragments that spanned both the invertible segment and the adjacent sequences required for inversion in E. coli (Fig. 3A). Several of the fragments were shifted in the presence of MBP-Piv (* in Fig. 3A). Two fragments, 430 and 870 bp, were chosen for further analysis by DNase I footprinting. The 430-bp fragment was selected because it spans the left recombination site of the invertible element (invL). The 870-bp fragment also contains the invL recombination site, plus a potential accessory site (see below).


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of MBP-Piv to the inversion region. A, a diagram of the labeled DNA fragments from the Moraxella inversion region used in gel electrophoretic mobility shift assays is shown (not to scale). Restriction sites used to create the DNA fragments are indicated (N is NcoI, B is BstXI, Sp is SpeI, R is EcoRV, and St is StyI). The length of each restriction fragment is given in base pairs. * marks the DNA fragments that EMSA indicated were specifically bound by MBP-Piv. The location of the MBP-Piv binding site is indicated by an X on the 850-bp fragment. B, a summary of the results from the DNase I protection assays with the 870-bp fragment (data not shown) and with the 298-bp fragment shown in C. The symbol # indicates a DNase I enhancement, and - marks protected bases. The numbering of the base pairs is relative to the first base pair of the invertible segment (+1). C, DNase I protection assays were performed as described under "Materials and Methods" on the top and bottom strands of the 298-bp fragment. + and - indicate the presence or absence of MBP-Piv, respectively. A/G and C/T are Maxam-Gilbert sequencing reactions. Arrows indicate sites of enhanced cleavage, while bars represent areas of protection. The positions of the first and last base of the DNase I protected regions are indicated to the right of the gels.

DNase I protection assays with MBP-Piv and the 870-bp fragment showed protections and enhancements from about -285 to -265 bp upstream of the invL cross-over site (data not shown). However, due to the relatively large size of the fragment, the DNase I cleavage pattern at the site was not easily resolved. Therefore, a smaller fragment of 298 bp, containing the protected DNA sequence, was examined by DNase I protection assays (Fig. 3, B and C).

The DNase I cleavage pattern in the MBP-Piv binding region has long tracts of no cleavage due to A-tract repeats that narrow the minor groove, thus inhibiting DNase I binding and cleavage (15). These A-tracts are also appropriately phased along the DNA helix to contribute sequence-directed DNA bending to this region of the DNA (16.). Protections and enhancements from -233 to -247 and from -266 to -285 (Fig. 3, B and C) could be resolved in these DNase I protection assays. No other protected regions were detected on the 298-bp fragment. This MBP-Piv binding site is probably too distant from the site of DNA cleavage (+1) and strand exchange in the inversion reaction to be the binding site for the Piv subunit that actually catalyzes the recombination reaction. However, it is likely that this Piv binding site is an accessory site utilized in the assembly of an active synaptic complex for Piv-mediated DNA inversion (see "Discussion").

The 430-bp fragment (Fig. 3A) contains the 26-bp site of inversion (invL) that was defined based upon sequence homology at the ends of the invertible segment (17). The initial EMSA analysis of MBP-Piv binding to the 430-bp fragment indicated that MBP-Piv does bind specifically, albeit weakly, to a sequence within this fragment (data not shown). However, DNase I and 1,10-phenanthroline-copper protection assays with the 430-bp fragment and MBP-Piv showed no evidence of protein-DNA interactions (data not shown). Because MBP-Piv does shift the 430-bp fragment in EMSA gels, indirect DNase I protection assays were performed with the 430-bp fragment in which the electrophoretically separated protein-DNA complex and unbound DNA are treated with DNase I in the non-denaturing polyacrylamide gel and then isolated from gel slices for electrophoresis on the DNA sequencing polyacrylamide gel (see "Materials and Methods"). Even though this assay should have enriched for DNA complexed with MBP-Piv, no protection of DNA sequence by MBP-Piv was observed. These results suggested that the binding of MBP-Piv to the 430-bp fragment was either unstable or not specific.

To determine if the poor interactions of MBP-Piv with invL are due to the MBP protein at the amino terminus of Piv, Piv was tagged at the COOH terminus with six histidines (see "Materials and Methods"). The Piv-His6 fusion protein was partially purified and used in EMSA and DNase I protection assays with the 430-bp fragment and also with the 298-bp fragment containing the accessory Piv binding site (data not shown). All of the DNA binding results with Piv-His6 corresponded exactly with those obtained with MBP-Piv, indicating that the poor binding of MBP-Piv to invL is not due to steric hindrance by MBP of Piv-specific binding. Therefore, stable binding of Piv may require other factors such as accessory DNA binding sites, accessory proteins, and/or supercoiled DNA substrate to facilitate binding to the recombination sites (see "Discussion").

Piv Binds Two Different Recognition Sequences-- To characterize the interactions of MBP-Piv with the isolated invL and upstream accessory site, double-stranded oligonucleotides corresponding to each site were synthesized (designated INV and SUB, respectively; Fig. 4A). The sequence of INV included the 26-bp region of homology from either end of the invertible element and 14 bp of sequence immediately upstream and downstream from the invL site. The DNA sequence of SUB (or strong upstream binding site oligonucleotide) was designed based on the DNase I footprint originally obtained with the 870-bp DNA fragment (i.e. the protected region -269 to -284, but not the -233 to -245 region). The INV and SUB DNA binding substrates were used in an EMSA to examine MBP-Piv binding at each site (Fig. 4B).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of MBP-Piv binding to the INV and SUB oligonucleotides. A, the positions of the INV and SUB oligonucleotides are indicated by bars above the diagram of the Moraxella inversion region. The oligonucleotide sequences are listed below this diagram. The possible 26-bp site of inversion is boxed in the INV sequence. The DNase I protected bases and enhanced cleavages within the SUB oligonucleotide are indicated as described in Fig. 3. B, EMSA was performed with labeled INV and SUB double-stranded oligonucleotides. The binding reactions were done as described under "Materials and Methods" and contained 32P-labeled INV and/or SUB and 63 nM MBP-Piv protein. The complexes formed between MBP-Piv and SUB are labeled S-1 and S-2. The complexes formed between MBP-Piv and INV are labeled as I-1 and I-2. The unbound INV and SUB substrates are labeled U. The lane numbers are indicated below the gel.

Two shifted complexes (S-1 and S-2, lane 2, Fig. 4B) were formed with the SUB oligonucleotide, indicating that at least two MBP-Piv proteins bind SUB. Because the SUB oligonucleotide does not include the DNA sequence from -233 to -247 bp (see Fig. 3), we have designated the MBP-Piv binding site encoded within the SUB oligonucleotide, sub1.

MBP-Piv binding to INV resulted in one primary complex (I-1) that migrated at approximately the same rate as the slower migrating complex formed with SUB (S-2). Because the difference in the molecular weights of the INV and SUB oligonucleotides is nominal in comparison to the MBP-Piv molecular weight, this result suggests that the I-1 and S-2 protein-DNA complexes contain the same number of MBP-Piv protomers. No faster migrating protein-DNA complex was seen with INV when the concentration of MBP-Piv was decreased (data not shown). The presence of a slower complex (I-2) was detected with some variability in the EMSAs. The formation of this complex suggests that a higher multimeric MBP-Piv may bind INV or an additional INV oligonucleotide may bind the I-1 complex.

Based upon the predicted molecular weights of INV, SUB, and MBP-Piv, the electrophoretic mobilities of I-1, S-1, and S-2 indicate that INV is bound by at least two MBP-Piv protomers while SUB is bound by either single (S-1) or multiple (S-2) MBP-Piv protomers. Comparison of the Piv DNA binding substrates, INV and SUB, revealed very little homology (TATNC), suggesting that Piv has two different DNA recognition sites.

Specificity of MBP-Piv Binding to INV and SUB-- To further examine the interactions of MBP-Piv with the apparently different binding sites on INV and SUB, competition assays were performed using each of the oligonucleotides as both binding substrate and competitor DNA. In Fig. 5A, the SUB oligonucleotide was labeled and used in DNA binding assays with MBP-Piv and the unlabeled competitor DNAs: SUB, INV, and the nonspecific oligonucleotide (see "Materials and Methods"). Although SUB competed for both S-1 and S-2 complex formation at 100- and 500-fold excess unlabeled oligonucleotide, INV competed effectively for only S-2 complex formation at the same molar excess of competitor DNA. This result is consistent with MBP-Piv interacting with invL only in a multimeric form (Fig. 4). The nonspecific DNA competitor also competed (less effectively) with SUB for MBP-Piv binding to give S-2 complex. This competition for S-2 complex formation by the nonspecific competitor may indicate that multimeric MBP-Piv protein has a faster off rate and so it is titrated out of the reaction by nonspecific protein-DNA interactions at 100-500-fold excess nonspecific competitor DNA. Fig. 5B shows that only the INV oligonucleotide effectively competed for MBP-Piv binding to labeled INV; SUB did not show significant competition even at 500-fold molar excess. These results again suggest a different interaction between MBP-Piv and invL as compared with binding of MBP-Piv to sub1.


View larger version (99K):
[in this window]
[in a new window]
 
Fig. 5.   Specificity of MBP-Piv binding to the INV and SUB oligonucleotides. Competition DNA binding assays were performed as described under "Materials and Methods" for both labeled INV and SUB. A, an EMSA gel is shown on which reactions containing 32P-labeled SUB oligonucleotide, 32 nM MBP-Piv protein, and cold competitor DNA were electrophoresed. The -fold molar excess of competitor DNA is indicated above each lane, and the lanes are grouped according to the competitor DNA used: INV, SUB, or nonspecific cold competitor DNA. Probe indicates the lane where no protein was added to the reaction. B, competition assays are shown in which each DNA binding reaction contained 32P-labeled INV oligonucleotide (see "Materials and Methods"), 630 nmol of MBP-Piv protein, and cold competitor DNA as indicated. The lanes are labeled as described in A. S-1, S-2, and I-1 indicate the same complexes as in Fig. 4, and U is the unbound DNA binding substrate. The nonspecific competitor oligonucleotide has no homology to the INV or SUB oligonucleotides.

Dissociation Rate Analysis-- The results of the DNase I footprinting, gel shift assays, and DNA binding competition analyses could be interpreted as indicating that the interactions of MBP-Piv with inv are less stable than with sub. The inability to obtain more than 40% of the INV DNA bound with increasing concentrations of MBP-Piv might be explained by a rapid dissociation rate for MBP-Piv when bound to the site of inversion, such that no more than 40% of the INV oligonucleotide complexed with MBP-Piv can be detected by the DNA binding assays used. Dissociation rate experiments with INV (Fig. 6A), using 5000-fold molar excess of competitor (unlabeled INV), showed that the percent bound DNA in the I-1 complex decreased >50% after 15 s of incubation with the competitor oligonucleotide. Surprisingly, even though 5000-fold excess INV competitor DNA prevented any complex formation when added before MBP-Piv (control lane in Fig. 6A), there was still close to 10% I-1 complex after a 1-h incubation of the preformed MBP-Piv-INV complex with 5000-fold excess unlabeled INV. The dissociation rate experiments with SUB (Fig. 6B) gave a half-life for the S-2 complex of about 15 s, similar to the I-1 complex. The S-1 complex, however, had a much higher half-life of 12 min, indicating that MBP-Piv binding as a single protomer in this complex is more stable. The apparent rapid dissociation rate of I-1 and S-2 is also consistent with multimerization of MBP-Piv producing an unstable protein complex.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Dissociation rates of MBP-Piv complexed with INV and SUB. Gel shift DNA binding assays are shown for protein-DNA complexes that were challenged with 5000-fold molar excess of competitor DNA. The percentage of bound DNA in each complex at each time point is represented on a graph. A, a dissociation rate assay performed with labeled INV produces a graph showing that the MBP-Piv protein bound in the I-1 complex has a half-life of about 15 s. B, a dissociation rate assay with SUB gives a result for both the S-1 (12-min half-life) and S-2 (15-s half-life) complexes as determined from the graph below the gel. S1, S2, and I-1 indicate the same complexes as in Fig. 4.

Examination of the Cooperativity of Piv Binding-- Cooperative interactions stimulate binding of multiple proteins to DNA sites. Therefore, cooperative binding of MBP-Piv may facilitate complex formation with the inv or sub sites where earlier results suggest that multiple protomers of MBP-Piv are binding. However, a multimeric form of MBP-Piv may bind noncooperatively if assembled in solution before binding to the inv or sub sites. To determine cooperativity, ln[P] versus ln ([PX]/[X]) was plotted producing a slope n, where [P] is the concentration of MBP-Piv protein added, and [PX] and [X] are the concentration of the bound and unbound DNA, respectively. For example, if MBP-Piv binds as a dimer to the DNA, n equal to 2 indicates that the binding of the two proteins is cooperative; n equal to 1 indicates that the binding is not cooperative, and therefore, the dimer is forming before binding to that DNA site (14).

To determine the cooperativity of MBP-Piv binding in the S-1 and S-2 complexes, increasing amounts of MBP-Piv were incubated with the 298-bp DNA fragment encoding the full sub site and subsequently analyzed by EMSA. Focusing on the MBP-Piv concentrations that gave the S-1 complex, the ratio of bound to unbound DNA was determined and compared with the concentration of MBP-Piv used. The ln[P] versus the ln([PX]/[X]) was plotted for binding reactions with 0.63 to 31.6 nM MBP-Piv (Fig. 7A). The slope of the resulting graph is 1, showing noncooperative binding by MBP-Piv at sub in the S-1 complex. Analysis of the S-2 complex revealed that Piv is binding cooperatively. The ln [P] versus the ln ([PX]/[X]) was plotted for binding reactions with 47.4 to 1580 nM MBP-Piv (Fig. 7A), and the resulting graph has a slope of 2, indicating that the binding is cooperative. This result supports the conclusion that at least two MBP-Piv proteins are binding to the sub site in the S-2 complex.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Cooperativity of MBP-Piv binding to the invL and sub sites. A, an EMSA gel is shown in which the labeled 298-bp fragment is incubated with increasing amounts of MBP-Piv. The results for the S-1 and S-2 complexes (see Fig. 4) are plotted as ln[P] versus ln([PX]/[X]), as described under "Results," for the range of MBP-Piv concentration that gives a single retarded complex and the range that gives two retarded complexes, respectively. B, the binding of MBP-Piv to the INV oligonucleotide is examined, and the results for the I-1 complex are plotted as above.

Cooperativity was also examined for Piv binding to the site of inversion using the INV oligonucleotide (Fig. 7B). The I-1 complex accumulated with increasing amounts of Piv. Again, no intermediate protein-DNA complex was seen. The ln[P] versus the ln[PX]/[X] was plotted for each lane, and the slope of the resulting graph is 0.6; this result indicates that noncooperative binding is occurring. Therefore, multimeric MBP-Piv must assemble in solution or at another site before binding to invL.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The site-specific recombinase Piv is a member of the novel family of DNA recombinases that includes the IS110/IS492 transposases (5). To determine the mechanism for DNA cleavage and strand exchange mediated by this unique DNA invertase, we must understand how Piv interacts with the chromosomal DNA segment that it inverts in M. lacunata. We have presented here DNA binding studies with MBP-Piv and DNA sequences from the type IV pilin inversion region of M. lacunata. The activity of the MBP-Piv fusion protein in these gel electrophoresis DNA binding assays and nuclease/chemical protection analyses is likely to correlate to the activity of wild type Piv, as MBP-Piv is active in vivo for DNA inversion (see Fig. 2).

Previous examination of the DNA sequence of the inversion region of M. lacunata revealed 26-bp inverted repeats, invL and invR, which defined the left and right ends of the invertible element (17, 18). Piv-mediated DNA cleavage and strand exchange must occur within these two 26-bp sequences for site-specific DNA inversion of the pilin segment. Therefore, based on other site-specific recombination and transposition systems (1, 2), it seemed likely that Piv binds to a DNA sequence overlapping or adjacent to invL and invR. The results of electrophoretic mobility shift assays indicate that MBP-Piv does indeed interact with DNA fragments containing both invL and invR, as well as with a few DNA fragments from both outside and within the invertible DNA segment of M. lacunata (see Fig. 3A). The binding of MBP-Piv to invL and one of the additional sites located outside of the invertible segment was further characterized.

MBP-Piv interactions with the invL site are quite weak, as indicated by the gel shift DNA binding assays in which less than 40% of the labeled DNA substrate (54-bp double-stranded INV oligonucleotide or 430-bp DNA fragment) could be specifically bound, no matter how high the concentration of MBP-Piv protein (see Fig. 7B and data not shown). In addition, MBP-Piv did not give a "footprint" at the invL site in either nuclease or chemical protection assays. Measurements of the dissociation rate for the MBP-Piv bound to invL (on INV, see Fig. 6A; or the 430-bp fragment, data not shown) show that the complex is unstable; the half-life of the complex is less than 15 s. While this weak binding of MBP-Piv to invL could have been due to the presence of the maltose-binding protein at the amino terminus of Piv, we found that Piv containing a small His6 tag at the COOH terminus also bound invL very weakly.

Piv is certainly not the first site-specific recombinase to exhibit poor affinity for the site where it mediates DNA cleavage and strand exchange. lambda  integrase (Int) binds very poorly to the "core" sites where it mediates DNA cleavage and strand exchange at the attP/attB or attL/attR sites. Cooperative interactions with Int bound to the "arm-type" sites and DNA bending mediated by IHF facilitate binding of Int to the core sites of attP and attL (19, 20). Int binds with very low affinity to the attB core sites (21); indeed, Int does not give a DNase I footprint at the core site of attR, even in the presence of the accessory proteins and arm-type sites (19).

lambda Int is a bivalent protein, having two different, separable DNA binding domains. The Int amino-terminal domain binds with high affinity to the arm-type sites, while the carboxyl-terminal domain binds weakly to the core sites and catalyzes DNA cleavage and strand exchange. Thus, monomers of Int can bridge the arm and core sites within att sites and bring att sites together in synapsis (20, 22). Because Piv binds so poorly to the invL site, we did not find it surprising that, like Int, Piv binds other DNA sequences that may facilitate the formation of a synaptic complex. The nuclease protection and gel shift DNA binding assays show that Piv binds with higher affinity to a different DNA recognition sequence located upstream of invL (Figs. 3, B and C, 4A, and 7, A and B). This strong upstream binding site (sub) is bound cooperatively by at least two protomers of MBP-Piv (see Figs. 4B and 7A). The dissociation rate assays (see Fig. 6B) performed with the sub site suggest that the first MBP-Piv protomer that binds to sub forms a stable complex (S-1) but the multimeric complex (S-2) is less stable.

The interactions of MBP-Piv with invL appear to differ from those with sub, not only in the affinity and stabililty, but also in the form of the protein required for binding to the site. The cooperativity assays and competition analyses suggest that only the multimeric form of MBP-Piv binds to invL, while single protomers of MBP-Piv bind cooperatively to sub (see Figs. 5 and 7). Again, this is not unusual behavior for a bivalent protein that mediates DNA recombination. The transposase of bacteriophage Mu, MuA, binds as a monomer to sites within the transpositional enhancer sequence which facilitates assembly of a synaptic structure (23, 24). But, MuA recognizes the recombination sites at the ends of the transposable element with a different domain of the protein, and then assembles a tetramer that is bound to both ends of the element on a supercoiled DNA substrate (25, 26). The interactions of MuA with the end recombination sites actually promote tetramer formation, and it is this complex that is active for recombination (27). In fact, under altered reaction conditions MuA can form a tetramer upon binding a single recombination site, but not on the enhancer sites (27). Therefore, when we consider the nature of the MBP-Piv complexes with sub and invL, it is possible that the sub site is an assembly site for the multimeric form of Piv that binds to the recombination sites. The instability of the MBP-Piv multimeric complex with invL may reflect the need for stabilization within a correct synaptic complex, like the binding of lambda  integrase to the core sites, or, perhaps Piv transiently interacts with the inv sites within an invertasome-like structure and the multimeric complex rapidly falls apart following catalysis of the recombination reaction. As has been suggested for a number of transposition and site-specific recombination systems (Ref. 28; for reviews see Refs. 1 and 2), it is undesirable for the recombinase to be active at recombination sites until a synaptic structure is assembled; this ensures that the correct strand exchange and religation occurs after DNA cleavage.

If sub acts as an assembly site for Piv, it is likely to stimulate the rate of inversion or to be required for Piv-mediated DNA inversion. Previous deletion analyses of the M. lacunata invertible segment and surrounding DNA sequences have shown that the region encoding the sub site is not essential for inversion of the Moraxella DNA segment in E. coli, although it may have an affect on the rate of inversion (14). Like the P2 arm site in lambda  attR (22), the sub site may be stimulatory only under certain conditions, such as when recombinase levels are low or in the presence/absence of accessory factors. Analysis of the nucleotide sequence of the inversion region using the GCG Wisconsin Package Bestfit program with the sub site sequence revealed two other possible sites within the 535-bp and 250-bp DNA fragments that were bound by MBP-Piv in the gel shift DNA binding assays (see Fig. 3A; data not shown). These other sites may substitute for the sub site or coordinately regulate the inversion reaction with sub. In order to define the roles of Piv and its different binding sites in the inversion reaction, we are currently using in vitro recombination assays to isolate intermediates in the DNA inversion reaction.

    ACKNOWLEDGEMENTS

We thank Gordon Churchward, Russell Karls, Charles Moran, and Maureen Powers for critical review of this manuscript and helpful discussions. We are grateful to Jeff Mahr for his contribution to the construction of pAG862.

    FOOTNOTES

* This work was supported by Public Health Service Grant GM49794-05 from the National Institutes of Health, by American Cancer Society Junior Faculty Research Award JFRA-501 (to A. C. G.), and by Presidential Young Investigator Award MCB-9396003 from the National Science Foundation (to A. C. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322. Tel.: 404-727-3734; Fax: 404-727-3659; E-mail: acglasg{at}bimcore.emory.edu.

1 D. Tobiason, A. Lenich, and A. C. Glasgow, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: IPTG, isopropyl-1-beta -D-galactopyranoside; PCR, polymerase chain reaction; bp, base pair(s); kb, kilkobase pair(s); MBP, maltose-binding protein; PAGE, polyacrylamide gel electrophoresis; EMSA, electrophoretic mobility shift assay.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Craig, N. L. (1996) in Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology (Neidhardt, F. C., ed), 2nd Ed., Vol. 2, pp. 2339-2362, American Society for Microbiology, Washington, DC
  2. Hallet, B., and Sherratt, D. J. (1997) FEMS Microbiol Rev 21, 157-178[CrossRef][Medline] [Order article via Infotrieve]
  3. Landy, A. (1993) Curr. Opin. Genet. Dev. 3, 699-707[Medline] [Order article via Infotrieve]
  4. Mahillon, J., and Chandler, M. (1998) Microbiol. Mol. Biol. Rev. 62, 725-774[Abstract/Free Full Text]
  5. Lenich, A. G., and Glasgow, A. C. (1994) J. Bacteriol. 176, 4160-4164[Abstract]
  6. Marrs, C. F., Rozsa, F. W., Hackel, M., Stevens, S. P., and Glasgow, A. C. (1990) J. Bacteriol. 172, 4370-4377[Medline] [Order article via Infotrieve]
  7. di Guan, C., Li, P., Riggs, P. D., and Inouye, H. (1988) Gene (Amst.) 67, 21-30[CrossRef][Medline] [Order article via Infotrieve]
  8. Maina, C. V., Riggs, P. D., Grandea, A. G. d., Slatko, B. E., Moran, L. S., Tagliamonte, J. A., McReynolds, L. A., and Guan, C. D. (1988) Gene (Amst.) 74, 365-373[CrossRef][Medline] [Order article via Infotrieve]
  9. Sambrook, J., Fritsch, E. F., and Maniatis, T. (eds) (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  10. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1991) Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York
  11. Glasgow, A. C., Bruist, M. F., and Simon, M. I. (1989) J. Biol. Chem. 264, 10072-10082[Abstract/Free Full Text]
  12. Maxam, A. M., and Gilbert, W. (1980) Methods Enzymol. 65, 499-560[Medline] [Order article via Infotrieve]
  13. Kuwabara, M. D., and Sigman, D. S. (1987) Biochemistry 26, 7234-7238[Medline] [Order article via Infotrieve]
  14. Kristensen, H. H., Valentin-Hansen, P., and Sogaard-Andersen, L. (1996) J. Mol. Biol. 260, 113-119[CrossRef][Medline] [Order article via Infotrieve]
  15. Drew, H. R., and Travers, A. A. (1984) Cell 37, 491-502[Medline] [Order article via Infotrieve]
  16. Koo, H. S., Drak, J., Rice, J. A., and Crothers, D. M. (1990) Biochemistry 29, 4227-4234[Medline] [Order article via Infotrieve]
  17. Fulks, K. A., Marrs, C. F., Stevens, S. P., and Green, M. R. (1990) J. Bacteriol. 172, 310-316[Medline] [Order article via Infotrieve]
  18. Rozsa, F., and Marrs, C. (1991) J. Bacteriol. 173, 4000-4006[Medline] [Order article via Infotrieve]
  19. Thompson, J. F., Moitoso de Vargas, L., Skinner, S. E., and Landy, A. (1987) J. Mol. Biol. 195, 481-493[Medline] [Order article via Infotrieve]
  20. Kim, S., Moitoso de Vargas, L., Nunes-Duby, S. E., and Landy, A. (1990) Cell 63, 773-781[Medline] [Order article via Infotrieve]
  21. Ross, W., and Landy, A. (1983) Cell 33, 261-272[Medline] [Order article via Infotrieve]
  22. Richet, E., Abcarian, P., and Nash, H. A. (1988) Cell 52, 9-17[Medline] [Order article via Infotrieve]
  23. Surette, M. G., and Chaconas, G. (1992) Cell 68, 1101-1108[Medline] [Order article via Infotrieve]
  24. Mizuuchi, M., Baker, T., and Mizuuchi, K. (1992) Cell 70, 303-311[Medline] [Order article via Infotrieve]
  25. Surette, M. G., Buch, S. J., and Chaconas, G. (1987) Cell 49, 253-262[Medline] [Order article via Infotrieve]
  26. Craigie, R., and Mizuuchi, K. (1987) Cell 51, 493-501[Medline] [Order article via Infotrieve]
  27. Baker, T., and Mizuuchi, K. (1992) Genes Dev 6, 2221-2232[Abstract]
  28. Merickel, S. K., Haykinson, M. J., and Johnson, R. C. (1998) Genes Dev. 12, 2803-2816[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.